Sugi Predict

Sugi Predict / Compounds / SCHEMBL6776290

SCHEMBL6776290

SCHEMBL6776290

Cn1cc([N+](=O)[O-])c(C(N)=O)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ ALDH1A1 P00352 3/20 0.54
▸ LMNA P02545 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ MITF O75030 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ ADORA2A P29274 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ NPY1R P25929 1/20 0.46
▸ NPY2R P49146 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1559275 0.84 L3MBTL1 (0.63) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL30079200 0.84 L3MBTL1 (0.59) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL17363317 0.82 L3MBTL1 (0.57) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL3467161 0.82 L3MBTL1 (0.61) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL19875767 0.81 L3MBTL1 (0.50) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL18049578 0.81 L3MBTL1 (0.69) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL18359307 0.81 ALDH1A1 (0.51) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL1558732 0.81 L3MBTL1 (0.60) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL18359320 0.80 ALDH1A1 (0.64) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2
SCHEMBL27834490 0.80 L3MBTL1 (0.40) L3MBTL1ALDH1A1LMNANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120020133-A Nitrogen-containing heterocyclic derivative and medical application thereof 杭州百新生物医药科技有限公司 2025-05-20 — — CN disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 — — US disclosed
EP-4395892-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 — — EP disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 — — CN disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 — — WO disclosed
CN-107709323-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-11-20 — — CN disclosed
EP-3267996-B1 PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME (US) 2020-11-11 — — EP disclosed
US-10829484-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2020-11-10 — — US disclosed
US-10829484-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2020-11-10 — — US disclosed
EP-3268003-B1 THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME (US) 2020-07-29 — — EP disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 — — EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 — — WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 — — US disclosed
US-6756373-B1 SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION PFIZER INC. 2004-06-29 — — US disclosed
EP-1123296-B1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER LTD (GB) 2003-09-17 — — EP disclosed
EP-1222190-A1 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS Pfizer Limited (GB) 2002-07-17 — — EP disclosed
US-6333330-B1 Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. 2001-12-25 — — US disclosed
EP-1123296-A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION Pfizer Limited (GB) 2001-08-16 — — EP disclosed
WO-2001027112-A1 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS PFIZER LIMITED (GB) 2001-04-19 — — WO disclosed
WO-2000024745-A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER LIMITED (GB) 2000-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 L3MBTL1 245/4885ALDH1A1 3559/4885LMNA 324/4885
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A L3MBTL1 3429/4885ALDH1A1 271/4885LMNA 2125/4885
US-10829484-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K11, PRKAR2B, MAP3K13 L3MBTL1 2100/4885ALDH1A1 4034/4885LMNA 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.